Icaria

We can capture 99% of urinary exosome using our nanowire device, and we are now working on early detection of cancer by analyzing miRNA profile extracted from urinary exosome.

Icaria is a business in deeptech based in Japan.

Profile

Icaria is a liquid biopsy startup, working on early detection of cancer. Icaria’s mission is to detect cancer early, accurately, and unpainfully. By accomplishing our mission, we want to provide accurate and unpainful early cancer detection method, and create a society that everyone can stay healthy throughout their lifetime. We have invented a nanowire device that can collect more than 99% of urinary exosome. By using this technology, we can extract about 1,300 species of miRNA , which is 5 times more than the conventional method. By analyzing the profile of miRNA by machine learning, we succeeded in creating an algorithm in order to diagnosis cancer.

Icaria is positioned in deeptech, a segment that rewards a clear, focused offering.

The company is recorded as being based in Japan.

Directory data places it at the Plug and Play portfolio startup stage.

Website: www.icariacorp.com